Dupilumab, a humanized monoclonal antibody, selectively inhibits the inflammatory signaling pathways mediated by interleukin-4 (IL-4) and IL-13, and is widely used in clinical practice for the treatment of atopic dermatitis and asthma (5, 6). This evidence concerns the gene IL4 and atopic eczema.